Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. on January 27, 2026, with the earliest event reported on the same date. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten directors.
- New Appointment: Dr. Samit Hirawat was appointed as a Class III director, effective immediately.
- Committee Assignment: Dr. Hirawat was concurrently appointed to the Science and Technology Committee.
- Independence: The Board determined that Dr. Hirawat qualifies as an independent director under Nasdaq listing standards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No risks, contingencies, or unusual items were disclosed in this report. Compensation for Dr. Hirawat will follow the Company's standard arrangement for non-employee directors, with no related party transactions reported.
Key Facts for Investor Verification
- Verify Dr. Samit Hirawat's professional background and qualifications for the Science and Technology Committee.
- Confirm the effective date of the Board size increase (January 27, 2026).
- Review the press release (Exhibit 99.1) for additional context on the appointment.